Overview

Intensive research on the pathogenesis of obesity has made anti-obesity therapies targeting specific receptors (Melanocortin 4 Receptor, Serotonin Receptor, OX receptor, etc.) a hot topic of research and new hope for a therapeutic modality. OX is a peptide neurotransmitter that is expressed predominantly by neurons in the lateral hypothalamic area. It stimulates appetite and plays a role in the regulation of sleep and wakefulness. The two receptors for OX, OX-1, and OX-2, show different affinities for different OX and exhibit different roles in metabolism and other behaviors. OX receptor modulators have been found to have potential as anti-obesity and anti-diabetic agents. Protheragen adheres to a client-first philosophy and offers a competitive anti-obesity therapy development service targeting the OX receptor.

Your Best Partner for Research on OX Receptor-Targeting Anti-Obesity Therapies

Our one-stop service for the development of anti-obesity therapies targeting the OX receptor includes everything from computer-aided drug design, compound synthesis, and preclinical studies to data analysis. As the ideal partner for anti-obesity therapeutics research, we are committed to creating customized solutions that exceed expectations and provide support at all stages of research. Specific services are listed below:

Anti-Obesity Drug Development

Computer-aided drug design: Our team includes researchers with deep scientific literacy and extensive experience working in computational chemistry. Based on advanced cheminformatics and modeling software, we rationally design anti-obesity drugs targeting OX receptors through molecular dynamics simulation and molecular docking based on theoretical computational methods of molecular structure. By analyzing and predicting the interactions between compounds and OX receptors, we design and optimize lead compounds, which greatly improves the level, speed, and success rate of drug design. We also perform drug-like properties assessment of potential anti-obesity drugs, including their absorption, distribution, metabolism, excretion, toxicity, etc., to filter out unsuitable compounds and improve the efficiency of research and development.

OX-1 receptor antagonist development: OX-1 receptor antagonists have been shown to reduce food intake and ultimately improve obesity. We develop highly potent and selective OX-1 receptor antagonists and analyze their binding affinity to the receptor by computer simulation. They are subsequently evaluated for anorexia, thermogenesis, and anti-obesity activity in obese models using obesity models.

OX-2 receptor modulator development: Enhanced OX-2 receptor signaling renders mice resistant to diet-induced obesity. OX-2 receptor selective agonist administration has been shown to inhibit high-fat diet-induced weight gain in mice. With our expertise in drug synthesis, we efficiently synthesize various OX-2 receptor modulators based on the prediction results and evaluate their effects on food intake, body weight, and other aspects.

Preclinical Studies of Anti-Obesity Therapies

Our research team combines a variety of cutting-edge technologies and highly efficient assays to evaluate the efficacy and therapeutic potential of anti-obesity drugs targeting the OX receptor. The assays are comprehensive and include safety, pharmacokinetics, pharmacodynamics, and bioassays. We are highly attentive to our client's research needs and focus on adopting a flexible approach.

Obesity models: Based on well-established experimental facilities and specialized modeling techniques, we offer a wide range of obesity models to study obesity and treatments.

In vitro studies: We have several types of in vitro cellular models to study the therapeutic efficacy of anti-obesity therapies targeting the OX receptor. The efficacy and safety of this therapy is assessed by analyzing metabolism, energy balance, etc.

In vivo studies: We select the appropriate route of administration for single and multiple dosing according to the characteristics of the anti-obesity drug. After a period of administration, changes in food intake, body weight, fat mass, gene expression profiles, etc., are detected in the animal model. The potential and safety of OX receptor antagonists in the treatment of obesity are assessed by accurate interpretation of the data.

Workflow

Applications

• OX and its receptors are associated with obesity, metabolic syndrome, and cancer. The development of anti-obesity therapies targeting OX receptors provides valuable information for obesity-related metabolic diseases and cancer research.
• Research on anti-obesity therapies targeting OX receptors helps advance obesity intervention research.
• Anti-obesity drug development targeting the OX receptor provides reliable information for combination therapy studies using multiple drugs simultaneously.

Advantages

• We have extensive research experience and are an exceptional service provider with unique strengths in the field of obesity research. We support all aspects of anti-obesity drug development targeting the OX receptor.
• We understand the uniqueness of each research project, carefully understand the specific research needs of our clients, and carefully tailor experimental solutions to help anti-obesity therapeutics targeting the OX receptor research projects progress smoothly.
• We have the experimental foundation and synthetic expertise to synthesize high-quality OX receptor modulators and evaluate their anti-obesity effects.

Innovative and Comprehensive Services

Publication

Frequently Asked Questions

How does computer-aided drug design drive the development of anti-obesity drugs targeting the OX receptor?

Our anti-obesity therapeutics research team encompasses experts in a variety of fields, including computational chemistry teams, medicinal chemistry teams, etc., to drive the optimization and development of anti-obesity drugs. After understanding the specific research objectives, our experts evaluate each project and apply appropriate computational chemistry methods for structure- and ligand-based modeling and analysis. In addition to this, we evaluate the drug-like properties of individual compounds to provide valuable information for the design and optimization of anti-obesity drugs targeting OX receptors.

What types of obesity models do we have to assess the therapeutic efficacy and safety of anti-obesity therapies targeting OX receptors?

We have extensive experience in obesity modeling and use a wide range of in vivo (mice, rats, rabbits, dogs, etc.) and in vitro models for preclinical studies of anti-obesity therapies. In addition, we also offer customization of obesity models to meet specific experimental needs.

Protheragen provides comprehensive services and reliable support for all phases of anti-obesity therapeutic research (therapeutic design to preclinical studies) targeting the OX receptor. Our stringent quality management system makes us the partner of choice for anti-obesity studies. Please feel free to contact us for details on all phases of anti-obesity therapy development targeting the OX receptor.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

• Targeting Cannabinoid Receptors (CB1 and CB2) for Developing Anti-Obesity Therapeutics
• Targeting Gastric Inhibitory Polypeptide (GIP) Receptor for Developing Anti-Obesity Therapeutics
• Targeting Glucagon Receptor (GCGR) for Developing Anti-Obesity Therapeutics
• Targeting Melanocortin 4 Receptor (MC4R) for Developing Anti-Obesity Therapeutics
• Targeting Peroxisome Proliferator-Activated Receptors (PPARs) for Developing Anti-Obesity Therapeutics
• Targeting Serotonin (5-HT) Receptors for Developing Anti-Obesity Therapeutics
• Targeting Sodium-Glucose Cotransporter for Developing Anti-Obesity Therapeutics